More on IVC/IAA (commentary)

[Guest guest]

[hsibaltimore.com]

 

Dear Reader,

 

Is it just a coincidence, or an exciting breakthrough in cancer

research?

Loretta Hill believes it's the latter.

Four years ago, Loretta was diagnosed with colon cancer. Surgery,

radiation and chemotherapy controlled the cancer at first, but a few

months later the cancer was back and had spread to her lungs. After

additional surgery her oncologist offered little hope that any treatment

would produce long-term survival.

 

Rather than proceed with a very expensive chemotherapy recommended by

her oncologist, Loretta contacted a Pennsylvania physician named

Vivienne Matalon, M.D., who treats cancer patients with vitamin C.

Lillian began receiving high doses of vitamin C given intravenously - a

method known as intravenous ascorbic acid (IAA). She still visits Dr.

Matalon to receive 30 grams of C each week, although there are no signs

that she currently has cancer.

So...is it a coincidence that Loretta and others have overcome dire

cases of cancer? Or are we on the verge of an important cancer treatment

breakthrough?

It will probably not surprise you at all that many mainstream doctors

and researchers want you to believe it's just a coincidence.

-----------

Case after case...

-----------

We can add Loretta Hill to our growing case file of cancer patients who

have been successfully treated with IAA.

In the e-Alert " Good News " (5/24/06), a prostate cancer patient named

Don Hemingway eloquently described how IAA brought his cancer under

control without surgery, chemotherapy or radiation. And in the e-Alert

" Just Getting Started " (4/11/06), I told you about three remarkable

cases in which IAA was used to treat kidney tumors, bladder cancer and

lymphoma.

 

Those latter three cases - reported in the Canadian Medical Association

Journal (CMAJ) last spring - were all overseen by Dr. Hugh D. Riordan,

founder and president of The Center for the Improvement of Human

Functioning International (CIHFI). Both Mr. Hemingway and Katie Wernecke

(the Texas girl with Hodgkin's disease) have been treated at CIHFI.

 

The investigation of the three case studies in CMAJ was led by Mark

Levine of the National Institute of Diabetes and Digestive and Kidney

Diseases. In a recent interview in the Philadelphia Inquirer, Dr. Levine

explained why he has come to focus his research on IAA for cancer while

the medical mainstream largely ignores the issue. He notes that the

American Cancer Society and other organizations dismiss IAA as a

cancer-fighter because the vitamin is an antioxidant. The concern is

that the therapy actually protects cancer cells from free radical

damage.

 

But Dr. Levine believes that just the opposite is true. His lab studies

have shown that when vitamin C reaches high concentrations it prompts

production of hydrogen peroxide, a potent oxidizing agent that attacks

cancer cells but leaves healthy cells undamaged.

-----------

Follow the money

-----------

Unfortunately, the mainstream closed the books on vitamin C cancer

therapy when two studies conducted in the 1970s showed that the vitamin

was ineffective in treating cancer. But both of those studies tested

oral supplements of vitamin C. In recent years, researchers such as Dr.

Riordan and Dr. Levine have demonstrated that the difference between

oral C or intravenous C is like the difference between logging on to the

Internet with dialup or DSL. Both dialup and oral C are useful, but they

can't do the important work that DSL and IAA can accomplish.

 

In the Inquirer article, Dr. Levine makes it clear that he's not trying

to prove to the world that IAA will revolutionize the treatment of

cancer - he's simply interested in putting IAA to the test. He says,

" The goal is: Find what's true. "

Simple enough, right? But he also notes that there's " tremendous

resistance " to mount significant clinical trials. Part of the resistance

stems from the antioxidant issue mentioned above. But what Dr. Levine

does not address is the powerful influence of the profit motive. Drug

companies and oncologists will not be able to reap much in the way of

profits from an IAA breakthrough. On the contrary, they're more likely

to lose a huge source of profits. So with cash cows in jeopardy, the

mainstream has little interest in devoting millions of dollars to mount

the necessary research.

 

" Information is diamonds. " That's how Dr. Levine characterizes the

importance of emerging case studies and other research that will

hopefully spur major IAA research. And according to the Inquirer there

is hope. Private funding will underwrite an upcoming University of

Kansas trial that will test IAA on 30 patients with ovarian cancer.

McGill University is also mounting an IAA trial with private funding.

 

Hmmm. Private funding. Now, if only there were a foundation funded by

America's two richest men...

**********************************************

Sources:

" Vitamin C: Cancer Cure " Marie McCullough, The Philadelphia Inquirer,

6/18/06, philly.com

" Intravenously Administered Vitamin C as Cancer Therapy: Three Cases "

Canadian Medical Association Journal, 3/28/06, cmaj.ca " In Memory of

Hugh D. Riordan, M.D. 1932-2005 " orthomolecular.org

**********************************************

To start receiving your own copy of the HSI e-Alert, visit:

http://www.hsibaltimore.com/ealerts/freecopy.html Or forward this e-mail

to a friend so they can sign-up to receive their own copy of the HSI

e-Alert.

**********************************************